Last reviewed · How we verify

NCT05664945: REPORT

Rethinking Pulmonary Rehabilitation - a Three-arm Randomised Multicentre Trial

Active, enrolled NA Last updated 6 March 2026
What this trial tests

NA trial testing pulmonary tele-rehabilitation (PTR) in Chronic Obstructive Pulmonary Disease in 180 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
10 January 2023
Primary endpoint
7 October 2025
31 July 2027

Quick facts

Lead sponsorCopenhagen University Hospital, Hvidovre
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment180
Start date10 January 2023
Primary completion7 October 2025
Estimated completion31 July 2027
Sites7 locations across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Copenhagen University Hospital, Hvidovre

Who can join

40 and older, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulmonary rehabilitation (PR) is one of the cornerstones of care for people with COPD together with smoking cessation and medical treatment. Despite the compelling evidence for its benefits, pulmonary rehabilitation is delivered to less than 30% of patients with COPD. Access to PR are particularly challenging, and especially for those with the most progressed stages of the disease. Pulmonary Tele-rehabilitation (PTR) and Home-based pulmonary rehabilitation (HPR) are two emerging models using health-care supportive technology that have proven equivalent to the conventional PR programs in patients with COPD who are able and willing to participate in conventional PR. However, much remain unknown regarding patients with COPD unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation. No studies have been conducted to specifically intervene towards this group. Response from emerging rehabilitation models for this specific group is a black box with no substantial research. To fulfill its potential of relevance, results from emerging models, such as Pulmonary Telerehabilitation and Home-based pulmonary rehabilitation must be of clinical relevance, and superior to the current 'usual care' (medication and scheduled follow-up control) in patients with COPD unable to access and participate in the conventional out-patient hospital- or community-based PR when offered during routine consultation.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Supervised pulmonary tele-rehabilitation and individualized home-based pulmonary rehabilitation for patients with COPD, unable to participate in center-based programs. The protocol for a multicenter randomized controlled trial - the REPORT study.
    Nielsen C, Godtfredsen N, Molsted S, Ulrik C, et al · · 2025 · cited 5× · PMID 39774509 · DOI 10.1371/journal.pone.0312742
  2. Why We Keep Going: A Qualitative Longitudinal Study of the Motivation and Engagement Among Patients with COPD During a Long-Term Danish Tele-Rehabilitation Program.
    Olsen M, Nielsen C, Emme C, Godtfredsen NS, et al · · 2025 · PMID 41257245 · DOI 10.2147/ppa.s549332
  3. Intra- and Inter-Rater Reproducibility of Measures of Physical Performance in Patients with COPD.
    Nielsen C, Godtfredsen N, Molsted S, Ulrik C, et al · · 2025 · PMID 41095835 · DOI 10.3390/jcm14196755

Verify or expand the search:

Other trials of pulmonary tele-rehabilitation (PTR)

Trials testing the same drug.

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Copenhagen University Hospital, Hvidovre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05664945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing